 |
 |
 |
|
|
|
|
The Global Vaccine Initiative
Situation Update; Capt Wardrobe - April 2021...
does not make any sense.
with
THIS REPORT ON VACCINE UPTAKE:
Global, regional, and national estimates of
target population sizes for covid-19 vaccination: descriptive study
date accepted by review at the British Medical Journal on 3rd December 2020
Authors: Wei Wang, doctoral candidate1, Qianhui Wu, doctoral candidate1, Juan Yang, associate researcher1, Kaige Dong, masters student1, Xinghui Chen, masters student1, Xufang Bai, masters student1, Xinhua Chen, masters student1, Zhiyuan Chen, masters student1, CĂ©cile Viboud, senior staff scientist2, Marco Ajelli, associate professor3 4, Hongjie Yu, professor1
|
Note:
The BMJ Paper [linked left] -
makes no reference to Mutations...Variants
apparently happening in Brazil, Africa etc
So we have a major study in vaccines here with no function once mutations are taken into consideration Are mutations to Sars Cov2 considered part of a pandemic? even though they are happening in isolated areas? There are no references made to re-infection. The report makes several recommendations, and assumes...in line with the prevalent medical theory...that once vaccinated the disease poses no risk...and that once enough people are vaccinated - as we saw with Smallpox, Herd immunity would be acheived. This rhetoric, however, goes against current narratives propagated in the mainstream media and vaccinations drives around the world. Continuous/annual Booster shots as regimen are being promoted. Indeed the following statement reveals that the current vaccine drive will not achieve herd immunity |
| "Twelve covid-19 vaccine manufacturers have announced their plans for vaccine production, with an estimated capacity of approximately 10 billion doses by the end of 2021. However, even in the highly optimistic scenario that 10 billion doses are effectively manufactured, with a two dose regimen (which is planned for most current covid-19 candidates), the existing annual production capacity is too limited to achieve herd immunity on a global scale (60-80% of the world population" |
|
This reference is made by the writers of the paper: to a 28 August 2020 "Science conversation" WHO's Chief Scientist, Dr Soumya Swaminathan explains herd immunity |
  |
Soumya: So, the SARS-CoV-2 virus is a highly transmissible virus. We think it needs at least 60 to 70% of the population to have immunity to really break the chain of transmission. If you allow this to happen naturally, it will take a long time, of course, but more importantly, it's going to do a lot of collateral damage. So even if 1% of people who get infected are ultimately going to die, then this can add up to a huge number of people, if we look at the global population. And that is why we believe it's not a good idea to try to achieve herd immunity by just letting the infection run wild in the population and infect a lot of people and that we should talk about herd immunity in the context of a vaccine.
Vismita: So, let me come to the vaccine now. So, our strategy is to vaccinate enough people rather than just letting people get infected. Is that where the science is now?
Soumya: That's right. Because with a vaccine you can achieve immunity and herd immunity safely. Through natural infection, we could also achieve it at some point, but it would be at great human cost. And so naturally, the better choice is doing it through a vaccine.
|
|
The vaccination of children is noted as a method to stop transmission |
|
"A third possible vaccine allocation scheme focuses on reducing SARS-CoV-2 transmission; in this case, high transmission groups should be targeted. Target populations include adults and children involved in economic or educational activities who experience higher risk of economic or educational harm from not working or going to school. These adults and children also have a higher probability of transmission when going back to work or school because of their large number of contacts" |
|
THIS STUDY OF FRENCH LOCKDOWN VIA THE LANCET published feb 2021 - STATES ITS OPENING PARAGRAPH;
"The extent to which very young children contribute to the transmission of SARS-CoV-2 is unclear."
and upon interpreting the test findings
"According to serological test results, the proportion of young children in our sample with SARS-CoV-2 infection was low. Intrafamily transmission seemed more plausible than transmission within daycare centres. Further epidemiological studies are needed to confirm this exploratory hypothesis."
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00024-9/fulltext
DO YOU THINK THIS IS GOOD ENOUGH EVIDENCE TO VACCINATE CHILDREN?
|
|
THE AIM IS TO VACCINATE 2 BILLION PEOPLE BY 2020-what?
WORLD POPULATION=7.9 BILLION PEOPLE
FOR TOTAL GLOBAL POPULATION VACCINATION
HOW MANY YEARS?
Do Mutations - escape variants etc mean this is all utterly futile?
Or is it the GOLDEN GOOSE? a cyclical economic model based on fear of disease as a control paradigm.
A Genetic Mrna vaccine experiment in how to try to contain an ever mutating virus - which, paradoxically is mutating because of the nature of the vaccination program itself.
Ever seen an impossible target,
drive production, demand & behavior?
CULT programming impossible to acheive = endless pandemic
Interestingly
Target Operating Modelling is done in The Computing industry
|
|
Is the world ready to produce a billion doses of a COVID-19 vaccine?
 | "When the software landscape is flexible and agile enough to deliver changing needs and requirements, then a good assumption would be to assume the organisation will eventually have to do the same. The organisation itself also needs to be flexible and agile to deliver the needs of society (not just existing clients). To do so, and following on from the Operating Model, the firm itself needs to be created, or re-designed in such a way that allows it to shift, flex and re-form to ensure its performance is optimal when the marketplace changes, which it will." oPUS nEBULA.COM |
HEY! I KNOW A COMPUTER GUY...
Pcr Testing for Covid has been purposefully over amplified to exaggerate cases
NOW ITS CYCLES ARE BEING BROUGHT TO LOWER LEVELS, AS VACCINES ARE ROLLED OUT.
|
 |
|
Has this been whole situation been turned into an industry model? - globalised, as a social impact disease
management business plan?
from what i can gather,
It is impossible to vaccinate the world.
This is an economic continuum
a free-dynamo of fear and control
A FORCE MULTIPLIER FOR A NEW GLOBAL PHARMACEUTICALS INDUSTRY
|
This video link to a report by Kim Iverson - refers to a leaked report of a Pfizer execs comments at a conference meeting - it gives the game away
see this CBS report too
|
|
BRUSSELS, April 21 (Reuters) - The European Union is paying 15.5 euros ($18.6) per dose of the Pfizer-BioNTech COVID-19 vaccine, according to the first contract it signed with the two companies which was leaked on Wednesday to Spanish newspaper La Vanguardia.
The price confirms what Reuters has reported in past months. Many media reported instead a lower number based on a document with partial prices briefly published on Twitter by a Belgian politician, who later deleted the tweet. .
The Belgian document, which included prices also for other jabs booked by the EU, fuelled the theory that the EU was facing delays in its vaccine supplies because it had paid too little. That was despite the AstraZeneca contract leaked in February that showed the price for that shot was higher than what was reported in the Belgian document.
Under the leaked contract with Pfizer, the EU agreed to pay on average 15.5 euros for the first 200 million doses. It also agreed to pay the same price for another 100 million optional doses which it ordered within a deadline set in the contract. Beyond that deadline it would have paid 17.5 euros per dose.
The EU in January signed a second contract for another 300 million doses with Pfizer-BioNTech that EU officials said kept the same price as the first contract.
The leaked contract also shows the EU gave Pfizer and BioNTech an upfront payment of 700 million euros in December to secure the first 200 million doses.
The bloc is now negotiating a third contract for a total of 1.8 billion doses with the two companies for 19.5 euros per dose, which would have stricter delivery conditions and the option for the EU to order enhanced vaccines against virus variants. ($1 = 0.8328 euros)
|
 |
 |
May 4, 2021
Last year, racing to develop a vaccine in record time, Pfizer made a big decision: Unlike several rival manufacturers, which vowed to forgo profits on their shots during the Covid-19 pandemic, Pfizer planned to profit on its vaccine.
On Tuesday, the company announced just how much money the shot is generating.
The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer's biggest source of revenue.
The company did not disclose the profits it derived from the vaccine, but it reiterated its previous prediction that its profit margins on the vaccine would be in the high 20 percent range. That would translate into roughly $900 million in pretax vaccine profits in the first quarter.
Pfizer has been widely credited with developing an unproven technology that has saved an untold number of lives.
source NY Times
|
|
The first “tweaked” vaccine against the worrying coronavirus variants that emerged in South Africa and Brazil has successfully neutralised them in laboratory trials, the US company Moderna has said.
The results of the small trial suggest that boosters against the variants will be feasible and could be rolled out this year to counter the threat from variants that have appeared around the world and are feared in some cases to be more transmissible or partially vaccine-resistant.
Leading companies have been racing to produce adapted versions of their Covid vaccines. Pfizer/BioNTech, which has a similar mRNA vaccine to Moderna’s, and Oxford/AstraZeneca are also in the process of developing tweaked vaccines against the South African variant, B1351, and the Brazilian variant, P1, which appear to be the major threat to current immunisation programmes.
Moderna became the first to announce results on Wednesday night. They appear to be very positive, although only basic information from an initial analysis of results is available so far.
The US company has tested both a booster shot of its standard Covid vaccine and also a tweaked version of the vaccine in people who have previously had the full double dose. Twenty adults were recruited for each arm of the trial, or 40 in total.
Two weeks after the new jab, Moderna says both the booster shot and the tweaked vaccine increased the antibodies in the blood that can neutralise the two variants of concern.
|
|
But the tweaked vaccine – called mRNA-1273.351 and designed specifically to combat the South African and Brazilian variants, which have similar mutations to the spike protein – produced higher levels of neutralising antibodies than the standard booster shot, mRNA-1273.
Moderna says it is also running a trial in which people are given a mixture of the booster and the vaccine specifically designed against the variant. It has submitted the early results as a paper to a pre-print server, it said in a statement. Once the combined trial is complete, it will produce a paper that will be published with peer review.
“As we seek to defeat the ongoing pandemic, we remain committed to being proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants,” said Stéphane Bancel, CEO of Moderna.
“Our mRNA platform allows for rapid design of vaccine candidates that incorporate key virus mutations, potentially allowing for faster development of future alternative variant-matched vaccines should they be needed … We will continue to make as many updates to our Covid-19 vaccine as necessary to control the pandemic.”
The vaccines have not been trialled in the field; these are blood samples analysed in the lab. But the regulatory authorities have said they would not need to go through the rigorous large-scale trials that were necessary for the original vaccines to obtain emergency approval.
The company said there were few side-effects from the vaccines and those that were reported were mild. Apart from pain at the injection site, the most common reported side-effects were fatigue, headache, muscle pain and joint pain.
|
 |
Your COVID vaccine booster might be a patch or a pill.
May 3, 2021 - While the Biden administration has been racing to maximize the number of Americans vaccinated against COVID-19, government researchers have also been working on what form the next generation of vaccines will take.
They may be combined with the seasonal flu vaccine, or could come in the form of pills or patches instead of shots. Scientists also envision vaccines that might shield against viruses beyond SARS-CoV-2 (the virus that causes COVID-19) that could avert future pandemics.
And they're evaluating whether those who are fully vaccinated might need booster shots later this year.
Additional shots could be virtually identical to the first doses, given as a safeguard against the possibility of waning immunity or tweaked to defend against mutant strains that are raising concerns.
|
